Cousolre, France
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
Phase
1Span
554 weeksSponsor
GlaxoSmithKlineJerez de la Frontera
Recruiting
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
This is a Phase III, randomized, open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig monotherapy versus Pembrolizumab monotherapy for the first-line treatment of participants with locally-advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.
Phase
3Span
320 weeksSponsor
AstraZenecaJerez de la Frontera
Recruiting
Effect of TXA Oral Sol 5% in Patients Treated With DOACs or VKA and Undergoing a Single or Multiple Tooth Extraction
The purpose of this study is to compare the efficacy, acceptability, and safety of Tranexamic Acid Oral Solution 5% with placebo in the prevention of clinically relevant bleeding events in subjects treated with direct oral anticoagulants or vitamin K antagonists and undergoing a single or multiple tooth extraction. A total of approximately 280 subjects will be randomized in two equal treatment groups (approximately 140 subjects per group) to receive Tranexamic Acid Oral Solution 5% or placebo solution for 7 days. Following screening, eligible subjects can be randomized within 14 days when all eligibility criteria are confirmed. Randomized subjects will undergo tooth extraction(s) and treatment period. The treatment period ends at Visit 5 followed by the follow-up period. The maximal study duration is about 4 weeks.
Phase
3Span
60 weeksSponsor
Hyloris DevelopmentsJerez de la Frontera
Recruiting
A Growth Artificial Intelligence Algorithm for leNgth and Weight Study
Phase
N/ASpan
63 weeksSponsor
Nutricia ResearchJerez de la Frontera
Recruiting
Healthy Volunteers
Treatment of High-risk Non-muscle Invasive Bladder Cancer With IMUNO BGC Moreau RJ as Prophylaxis
Phase
2Span
146 weeksSponsor
Biofabri, S.LJerez de la Frontera
Recruiting
A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma
Phase
N/ASpan
337 weeksSponsor
Janssen Pharmaceutica N.V., BelgiumJerez de la Frontera
Recruiting
Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma
The study will enroll participants with moderate to severe uncontrolled asthma who are on low-dose inhaled corticosteroid (ICS) - a long-acting beta-agonist (LABA) or medium-to-high-dose ICS with or without LABA background treatment. The study will be initiated by Lead-in pharmacokinetics (PK) cohort in asthma participants. Participant will be randomised globally, including participants in Lead-in PK cohort (2 arms) and in Part 1 of the study (2 arms). In the Lead-in PK cohort, participants will be randomised to Atuliflapon or placebo (recruitment completed). In Part 1 of the study, participants will be stratified by geographical region, and grouped based on high or low levels of biomarker at screening (Visit 1).
Phase
2Span
209 weeksSponsor
AstraZenecaJerez de la Frontera
Recruiting
Niraparib with BeVAcizumab After Complete CytoreductioN in Patients with OvArian Cancer
Phase II, randomized, open label, multicenterstudy. Randomization on a 1:1 ratio, stratification performed according to: BRCA status (local assessment) FIGO stage at diagnosis (IIIA versus IIIB/IIIC) Previous hyperthermic intraperitoneal chemotherapy (yes/no).
Phase
2Span
422 weeksSponsor
ARCAGY/ GINECO GROUPJerez de la Frontera
Recruiting
A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI)
Phase
N/ASpan
134 weeksSponsor
Janssen Research & Development, LLCJerez de la Frontera
Recruiting
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
Phase
2/3Span
211 weeksSponsor
Kartos Therapeutics, Inc.Jerez de la Frontera
Recruiting